多中心EMBRACE I研究中T评分评估宫颈癌放化疗期间消退的预后意义
基于EMBRACE I研究1416例中1318例可评估T评分(TS)的患者,在诊断时(TSD)和近距离治疗时(TSBT)分别计算TS。TS消退见于71%的患者,与近距离治疗技术、剂量体积直方图参数、局部控制、生存及发病率相关;TS消退(TSBT≤5)者局部控制与生存改善、发病率更低。
要点
- TS整合临床检查与MRI所示原发肿瘤8个解剖部位侵犯情况,诊断时与近距离治疗时分别评分。
- TS消退见于71%患者,且为近距离治疗技术及CTVHR D90、膀胱D2cm3、直肠D2cm3等剂量体积参数的 explanatory variable。
- TSBT≤5(消退)较TSBT>5者局部控制与生存改善、发病率更低;多因素分析中TS消退对局部控制和生存均显著。
核心结论
- TS在多中心 setting 中得到验证,被证明是整合临床发现与影像的强有力多学科平台,能定量局部肿瘤消退及其对近距离治疗技术、剂量体积直方图参数、局部控制、生存和发病率的预后意义。
研究设计与样本
- EMBRACE I多中心研究纳入1416例患者,其中1318例可进行TS评估;患者接受放化疗后行MRI引导近距离治疗。
主要发现
- TSD中位数为5,TSBT中位数为4;TS消退见于71%的患者。
- TS消退是近距离治疗技术(腔内 vs 腔内/组织间)及CTVHR、CTVHR D90、膀胱D2cm3、直肠D2cm3等主要剂量体积直方图参数的 explanatory variable。
- TS消退(TSBT≤5)较TSBT持续高(>5)者局部控制与生存改善、发病率更低。
- TS消退与患者、疾病和治疗相关的已确立预后参数联合分析时,对局部控制和生存的多因素分析均显著。
关键数值与推荐
- TS采用0至3分排序量表评估宫颈癌局部侵犯典型的8个解剖部位,诊断时(TSD)和近距离治疗时(TSBT)分别计算8个部位得分之和。
- TSBT≤5定义为TS消退,TSBT>5定义为TS持续高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A simple scoring system (T-score, TS) for integrating findings from clinical examination and magnetic resonance imaging (MRI) of the primary tumor at diagnosis has shown strong prognostic capability for predicting local control and survival in locally advanced cervical cancer treated with chemoradiation and MRI-guided brachytherapy (BT). The aim was to validate the performance of TS using the multicenter EMBRACE I study and to evaluate the prognostic implications of TS regression obtained during initial chemoradiation. METHODS AND MATERIALS: EMBRACE I recruited 1416 patients, of whom 1318 were available for TS. Patients were treated with chemoradiation followed by MRI-guided BT. A ranked ordinal scale of 0 to 3 points was used to assess 8 anatomic locations typical for local invasion of cervical cancer. TS was calculated separately at diagnosis (TSD) and at BT (TSBT) by the sum of points obtained from the 8 locations at the 2 occasions. RESULTS: Median TSD and TSBT was 5 and 4, respectively. TS regression was observed in 71% and was an explanatory variable for BT technique (intracavitary vs intracavitary/interstitial) and major dose-volume histogram parameters for BT, such as high-risk clinical target (CTVHR), CTVHR D90 (minimal dose to 90% of the target volume), D2cm3 bladder (minimal dose to the most exposed 2 cm3 of the bladder), and D2cm3 rectum. TS regression (TSBT≤5) was associated with improved local control and survival and with less morbidity compared with patients with TSBT remaining high (>5) despite initial chemoradiation. TS regression was significant in multivariate analysis for both local control and survival when analyzed in consort with already established prognostic parameters related to the patient, disease, and treatment. CONCLUSIONS: TS was validated in a multicenter setting and proven to be a strong multidisciplinary platform for integration of clinical findings and imaging with the ability to quantitate local tumor regression and its prognostic implications regarding BT technique, dose-volume histogram parameters, local control, survival, and morbidity.
引用
- Lindegaard JC, Petric P, Schmid MP, et al. Prognostic Implications of Uterine Cervical Cancer Regression During Chemoradiation Evaluated by the T-Score in the Multicenter EMBRACE I Study. Int J Radiat Oncol Biol Phys. 2022. PMID: 35157992. doi:10.1016/j.ijrobp.2022.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。